Positive Results From ProDERM Study of octagam ® 10% in Patients With Dermatomyositis Meeting the Primary Endpoint Will Be Presented at ACR Convergence 2020
Octapharma announces that the final results from the phase III ProDERM study will be presented at the American College of Rheumatology (ACR) Convergence 2020 virtual meeting. The ProDERM study assessed the long-term efficacy, tolerability and safety of octagam® 10%, an intravenous immunoglobulin (IVIg), in patients with dermatomyositis.
- The primary endpoint of the study was met, with a significantly higher proportion of responders in the octagam® 10% group compared with the placebo group (78.7% vs 43.8%; p=0.0008)
- The response in the octagam® 10% group in the First Period of the study was maintained for all efficacy endpoints through the open-label Extension Period
- The majority of adverse events were mild in intensity and octagam® 10% was generally well tolerated in this population of patients with dermatomyositis.
Dermatomyositis is a rare systemic autoimmune disease of unknown cause, which targets muscle and/or skin and other organs. Patients suffer from skin rashes, chronic muscle inflammation leading to muscle weakness, and have a 10-year survival rate of approximately 50%1. While there are no proven and approved treatments for dermatomyositis, some patients receive off-label IVIG therapy2 but data from large randomized placebo-controlled studies of IVIG in these patient population are scarce. The US Food and Drug Administration (FDA) granted Octapharma an Orphan Drug designation for octagam® 10% for the treatment of patients with dermatomyositis in May 2017.
The ProDERM study was the first pivotal randomised clinical trial to evaluate IVIg for dermatomyositis. In an initial 16-week double-blind placebo-controlled period, patients were randomised to receive either high-dose octagam® 10% (2g/kg) or placebo every four weeks. This was followed by an open-label extension period during which all patients received octagam® 10% every four weeks for a further 24 weeks (excluding patients who had shown clinical worsening while receiving octagam® 10% in the initial 16 weeks). The primary endpoint was the proportion of patients who responded to treatment at Week 16, as defined by an improvement of ≥ 20 points on the Total Improvement Score (TIS) of the 2016 ACR/European League Against Rheumatism (EULAR) myositis response criteria3. The TIS is based on six myositis core set measures: Manual Muscle Testing, Physician Global Disease Activity, Patient Global Disease Activity, Health Assessment Questionnaire, Muscle Enzyme and Extra-muscular Disease Activity.
The study enrolled 95 patients from 36 sites in 10 countries. “The design of the ProDERM study, allowing patients to switch treatment if they deteriorated, facilitated recruitment of a large number of patients for such a rare disease” said Rohit Aggarwal, MD MS, University of Pittsburgh, member of the ProDERM study Steering Committee. “The rather large patient population of this study compared to former smaller studies make the results much better applicable in the clinic, especially in view of the very heterogenous nature of this disease.”
At Week 16, 78.7% (37/47) of patients receiving octagam® 10% were responders compared with 43.8% (21/48) of patients receiving placebo. A supportive analysis of the primary endpoint showed a significantly higher mean TIS in the octagam® 10% group (47.7) compared to the placebo group at Week 16 (21.3, p<0.0001). By the end of the open-label Extension Period at Week 40, 69.6% (32/46) of the patients who had switched from placebo to octagam® 10% were responders, demonstrating that patients initially randomised to placebo improved after switching to octagam® 10%. The response rate in patients in the IVIG group was maintained until Week 40 (71.1%; 32/45). The safety and tolerability profile showed that administration of octagam® 10%was generally well tolerated in this patient population.
“Until now, patients with dermatomyositis had poor prognosis and a lack of approved treatment options”, said Olaf Walter, Board Member at Octapharma. “We are very excited by the positive results of the ProDERM study. Improving the lives of patients is central to Octapharma’s mission, and we are proud to share these data with the aim of making effective therapy available to patients with dermatomyositis.”
The results of the ProDERM study demonstrated the efficacy, safety and tolerability of octagam® 10% in patients with dermatomyositis and are the first to show a clinical benefit from a large randomized placebo-controlled study of IVIg in dermatomyositis patients.
About the ProDERM study
The Progress in DERMatomyositis study (ProDERM, NCT02728752) was an international multi-centre double-blind, randomised, placebo-controlled phase III clinical trial that investigated the efficacy, safety and tolerability of octagam® 10% in patients with dermatomyositis. The ProDERM study enrolled 95 patients from 36 sites in 10 countries.
About octagam® 10%
Octagam® 10% is a ready to use, liquid preparation of highly purified human immunoglobulin for intravenous administration. Octagam® 10%is approved for idiopathic thrombocytopenic purpura in the USA, Europe and Canada. It is also approved for use in treatment of primary immunodeficiency, secondary immunodeficiencies and Guillain Barré syndrome in Europe and Canada and for CIDP in Europe.
Dermatomyositis is a rare immune-mediated inflammatory myositis characterised by skin rashes on the eyelids, chest, and joints of the hands as well as proximal muscle weakness secondary to chronic skin and muscle inflammation, respectively4. Despite significant morbidity and mortality associated with dermatomyositis, there are no clinically proven therapies approved by the US or European regulatory authorities for the treatment of dermatomyositis.
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.
Octapharma employs more than 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Haematology, Immunotherapy, and Critical Care.
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, with a combined capacity of approximately 8 million litres of plasma per annum.
In addition, Octapharma operates more than 140 plasma donation centres across Europe and the USA.
- Airio A, et al. Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006; 25:234-239.
- Ho C and Visintini S. Off-Label Use of Intravenous Immunoglobulin for Dermatological Conditions: A Review of Clinical Effectiveness. Canadian Agency for Drugs and Technologies in Health. 20 April 2018.
- Aggarwal R, et al. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis. Arthritis Rheumatol 2017; 69:898-910.
- Findlay AR, et al. An overview of polymyositis and dermatomyositis. Muscle Nerve 2015; 51:638-656.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
0041 55 451 21 21
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
I’mbesideyou Inc. Launched “UNION OF EMOTIONS” Service Using AI to Visualize Cheering Each Other Across National Borders30.7.2021 16:25:00 CEST | Press release
I’mbesideyou Inc. (Setagaya-ku, Tokyo CEO: Shozo Kamiya, hereinafter referred to as I'mbesideyou) launched the "UNION OF EMOTIONS" service on July 23, 2021, the opening day of an international sporting event. This is the first time we have been able to visualize people cheering each other with emotion analysis AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210730005404/en/ A visualization of the emotions of cheers flying around the world: Click on each cheer to learn more about that country. (Photo: Business Wire) More than 20,000 cheers have already been sent from more than 79 cities across more than 14 countries around the world, and the sight of the cheers flying across the globe has moved many people on social media. UNION OF EMOTIONS, is the world's first example of people's emotions connecting in real time across countries with the help of AI. It is scheduled to be available until August 8, when the closing ceremon
Palace Bidco Oy (“WSIP Bidco”) Has Received Necessary Regulatory Approval Concerning the Recommended Cash Offer to the Shareholders of Adapteo Plc (“Adapteo”)30.7.2021 14:23:00 CEST | Press release
This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden or Finland who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this announcement and in the offer document which was published on 23 June 2021. Shareholders in the United States should also refer to the section titled “Special notice to shareholders in the United States” at the end of this announcement and in the offer document. On 17 May 2021, WSIP Bidco, a private limited liability company formed on behalf of, and indirectly wholly owned by, West Street Global Infra
Taipei Exchange Launches Pioneer Stock Board to Support Innovative Enterprises30.7.2021 10:00:00 CEST | Press release
The Taipei Exchange, TPEx, launched Pioneer Stock Board (PSB) on July 20, 2021, which welcomed its first company on July 26. Pioneer Stock Board marks the evolution of the stock market into an innovation-friendly ecosystem. It aims to facilitate entry to capital markets for more innovative enterprises. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210730005008/en/ Taipei Exchange launches Pioneer Stock Board to support innovative enterprises (Photo: Business Wire) At the PSB Launch Ceremony, Premier Su Tseng-chang delivered the opening speech, emphasizing the government’s support. Su said, “Taiwan’s capital market breaks new ground today, by establishing this board. PSB will support innovative enterprises, a key driver of economic transformation, by providing companies with quick access to capital needed for continued growth.” Dr. Tien-mu Huang, Chairperson of Financial Supervisory Commission, remarked, “Innovation underpin
ITRS Group Continues Expansion With the Acquisition Of Opsview30.7.2021 10:00:00 CEST | Press release
ITRS Group, a leading provider of real-time monitoring and analytics software, has acquired 100% of Opsview Limited, a modern, scalable monitoring platform, which provides unified insight into dynamic IT operations on-premises, in the Cloud or hybrid. Opsview will remain and operate as a separate brand and entity. The purchase of Opsview aligns well with ITRS’ strategy to build, buy and partner to deliver smart, automated and predictive end-to-end monitoring solutions for increasingly complex IT estates across industries. This development follows the successful strategic acquisitions of Sumerian, OP5 and Uptrends. Guy Warren, CEO of ITRS commented: “Opsview is trusted by hundreds of businesses, government organisations and service providers globally. This acquisition will enhance our technological innovation, increase our portfolio capability, and provide continued expansion across our global support services.” Mike Walton, CEO and founder of Opsview said: “Partnering with ITRS represe
Schneider Electric Moves Forward With Its Sustainability Impact Targets, Mobilizing Support From Employees, Partners and Customers30.7.2021 08:32:00 CEST | Press release
Schneider Electric, the leader in the digital transformation of energy management and automation, published today its half-year progress overview on setting up and advancing on its 2021-2025 sustainability impact targets. Schneider Electric, named as the world’s most sustainable corporation 2021 by the Corporate Knights Global 100 Index, announced the acceleration of its sustainability strategy in January, aligned to its commitments regarding climate, resources, trust, equal opportunities, generations, and local communities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729006295/en/ Schneider Sustainability Impact - H1 Results (Graphic: Business Wire) Since then, the Group has successfully launched The Zero Carbon Project, its initiative to halve carbon emissions of its top supply chain partners by 2025, a call to action already joined by 91% of them. By engaging, training, and supporting the sustainable transformation
Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress30.7.2021 08:00:00 CEST | Press release
Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the first quarter of fiscal year 2021 (period ended June 30, 2021). Based on the solid first-quarter results, the Company also confirmed its fiscal year 2021 management guidance and forecast. Fiscal year 2021 remains a year of inflection with Takeda positioned for topline acceleration and continued pipeline progress, including critical regulatory submissions, potential approvals and additional new molecular entities (NMEs) advancing in pivotal studies. Costa Saroukos, Chief Financial Officer, commented: “With the Shire integration behind us and continued transformation over the last two years, we’ve pivoted towards accelerating topline growth and investing in R&D to fuel our highly innovative pipeline. Takeda’s first-quarter results demonstrate the continued strength of our 14 global brands and, with the business momentum from this strong start to our fiscal year, we remain on t
Conviva and the Trade Desk Partner to Improve Contextual Advertising for Premium Streaming Publishers29.7.2021 19:04:00 CEST | Press release
Conviva, the intelligence cloud for streaming media, and global advertising technology leader The Trade Desk, have entered a first-of-its-kind partnership to provide the streaming advertising industry the contextual content signals needed in the bidstream to improve their connected TV campaigns based on signals and effectiveness. Together, the two companies will help premium publishers supply programmatic buyers with the network, genre, rating, length and other detailed data sorely lacking in the streaming industry while still maintaining data control. Details of the partnership, product offering, participating publishers and how premium publishers can participate and benefit, will be available via a webinar in August. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210729005953/en/ The Trade Desk + Conviva (Graphic: Business Wire) According to Conviva’s State of Streaming Advertising report, released in June 2021, only 39% o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom